Dupont Capital Management Corp Trims Holdings in Bristol-Myers Squibb Co (BMY)

Dupont Capital Management Corp cut its holdings in shares of Bristol-Myers Squibb Co (NYSE:BMY) by 3.8% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 158,184 shares of the biopharmaceutical company’s stock after selling 6,182 shares during the quarter. Dupont Capital Management Corp’s holdings in Bristol-Myers Squibb were worth $9,820,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in the business. BlackRock Inc. lifted its holdings in Bristol-Myers Squibb by 7.2% during the 2nd quarter. BlackRock Inc. now owns 111,913,559 shares of the biopharmaceutical company’s stock worth $6,193,296,000 after buying an additional 7,517,623 shares in the last quarter. Massachusetts Financial Services Co. MA lifted its holdings in Bristol-Myers Squibb by 44.3% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 9,460,148 shares of the biopharmaceutical company’s stock worth $587,287,000 after buying an additional 2,903,920 shares in the last quarter. Janus Henderson Group PLC lifted its holdings in Bristol-Myers Squibb by 114.5% during the 2nd quarter. Janus Henderson Group PLC now owns 6,922,917 shares of the biopharmaceutical company’s stock worth $383,119,000 after buying an additional 3,695,485 shares in the last quarter. Schwab Charles Investment Management Inc. lifted its holdings in Bristol-Myers Squibb by 2.8% during the 2nd quarter. Schwab Charles Investment Management Inc. now owns 6,283,205 shares of the biopharmaceutical company’s stock worth $347,713,000 after buying an additional 172,417 shares in the last quarter. Finally, Bank of Montreal Can lifted its holdings in Bristol-Myers Squibb by 13.9% during the 3rd quarter. Bank of Montreal Can now owns 5,862,162 shares of the biopharmaceutical company’s stock worth $363,924,000 after buying an additional 717,503 shares in the last quarter. Institutional investors own 72.54% of the company’s stock.

Shares of BMY opened at $53.39 on Friday. Bristol-Myers Squibb Co has a twelve month low of $46.94 and a twelve month high of $70.05. The firm has a market capitalization of $86.49 billion, a PE ratio of 17.74, a PEG ratio of 1.48 and a beta of 1.08. The company has a current ratio of 1.53, a quick ratio of 1.40 and a debt-to-equity ratio of 0.41.

Bristol-Myers Squibb (NYSE:BMY) last announced its quarterly earnings data on Thursday, October 25th. The biopharmaceutical company reported $1.09 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.91 by $0.18. The business had revenue of $5.69 billion for the quarter, compared to analyst estimates of $5.72 billion. Bristol-Myers Squibb had a net margin of 6.50% and a return on equity of 47.89%. Equities analysts expect that Bristol-Myers Squibb Co will post 3.88 EPS for the current year.

The business also recently announced a quarterly dividend, which was paid on Thursday, November 1st. Investors of record on Friday, October 5th were given a $0.40 dividend. This represents a $1.60 dividend on an annualized basis and a dividend yield of 3.00%. The ex-dividend date was Thursday, October 4th. Bristol-Myers Squibb’s dividend payout ratio (DPR) is 53.16%.

A number of research firms have issued reports on BMY. Jefferies Financial Group set a $58.00 target price on shares of Bristol-Myers Squibb and gave the stock a “hold” rating in a report on Sunday, July 15th. ValuEngine upgraded shares of Bristol-Myers Squibb from a “sell” rating to a “hold” rating in a report on Saturday, July 14th. Atlantic Securities upgraded shares of Bristol-Myers Squibb from an “underweight” rating to a “neutral” rating and set a $57.00 price objective on the stock in a report on Wednesday, August 8th. Barclays raised their price objective on shares of Bristol-Myers Squibb from $55.00 to $58.00 and gave the company an “equal weight” rating in a report on Friday, October 12th. Finally, Credit Suisse Group restated a “hold” rating and issued a $61.00 price objective on shares of Bristol-Myers Squibb in a report on Wednesday, September 12th. Two research analysts have rated the stock with a sell rating, twelve have issued a hold rating and seven have given a buy rating to the company. Bristol-Myers Squibb currently has an average rating of “Hold” and an average target price of $62.48.

WARNING: This piece was first published by American Banking News and is the property of of American Banking News. If you are viewing this piece on another site, it was stolen and republished in violation of U.S. & international copyright & trademark legislation. The legal version of this piece can be viewed at https://www.americanbankingnews.com/2018/11/10/dupont-capital-management-corp-trims-holdings-in-bristol-myers-squibb-co-bmy.html.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. The company offers drugs in various therapeutic classes, such as oncology; cardiovascular; immunoscience; and virology, including human immunodeficiency virus (HIV) infection.

Featured Article: Reverse Stock Split

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply